JPH0343401A - 置換されたポリサツカライドおよびその製法 - Google Patents

置換されたポリサツカライドおよびその製法

Info

Publication number: JPH0343401A
Authority: JP; Japan
Prior art keywords: group; substituted; polysaccharide; sulfate; formula
Prior art date: 1989-07-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2170400A

Other languages

English (en)

Japanese (ja)

Inventor

Michael Dr Magerstaedt

ミヒアエル・マーゲルシユテート

Merten Schlingmann

メルテン・シュリングマン

Elmar Dr Schrinner

エルマル・シユリナー

Axel Walch

アクセル・ヴアルヒ

Matthias Wiesner

マテイーアス・ヴイースナー

Irvin Dr Winkler

イルヴイン・ヴインクラー

Hubert Bader

フーベルト・バーダー

Arnold Dr Paessens

アーノルト・ペーゼンス

Lothar Dr Biesert

ロータル．ビーゼルト

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hoechst AG

Original Assignee

Hoechst AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-01

Filing date

1990-06-29

Publication date

1991-02-25

1990-06-29 Application filed by Hoechst AG filed Critical Hoechst AG

1991-02-25 Publication of JPH0343401A publication Critical patent/JPH0343401A/ja

Status Pending legal-status Critical Current

Links

229920001282 polysaccharide Polymers 0.000 title claims abstract description 65
239000005017 polysaccharide Substances 0.000 title claims abstract description 65
238000004519 manufacturing process Methods 0.000 title claims 3
150000004676 glycans Chemical class 0.000 title abstract 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 32
-1 (substituted) amino group Chemical group 0.000 claims abstract description 26
241000700605 Viruses Species 0.000 claims abstract description 26
150000001768 cations Chemical group 0.000 claims abstract description 11
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 10
239000000178 monomer Substances 0.000 claims abstract description 7
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 4
229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 4
229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 4
230000001180 sulfating effect Effects 0.000 claims abstract description 3
239000004215 Carbon black (E152) Substances 0.000 claims abstract 2
229930195733 hydrocarbon Natural products 0.000 claims abstract 2
150000004804 polysaccharides Chemical class 0.000 claims description 60
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 42
229920002307 Dextran Polymers 0.000 claims description 37
229960002086 dextran Drugs 0.000 claims description 37
150000001875 compounds Chemical group 0.000 claims description 28
229960000633 dextran sulfate Drugs 0.000 claims description 25
229920001221 xylan Polymers 0.000 claims description 21
238000000034 method Methods 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
239000000126 substance Substances 0.000 claims description 13
150000002148 esters Chemical class 0.000 claims description 10
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 9
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
150000004823 xylans Chemical class 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 7
230000003612 virological effect Effects 0.000 claims description 7
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
229920000669 heparin Polymers 0.000 claims description 6
229960002897 heparin Drugs 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 4
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 4
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 4
239000001913 cellulose Substances 0.000 claims description 4
229920002678 cellulose Polymers 0.000 claims description 4
235000010980 cellulose Nutrition 0.000 claims description 4
239000011159 matrix material Substances 0.000 claims description 4
150000001350 alkyl halides Chemical class 0.000 claims description 3
125000003277 amino group Chemical group 0.000 claims description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 3
150000002431 hydrogen Chemical class 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
230000005764 inhibitory process Effects 0.000 claims description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
235000019698 starch Nutrition 0.000 claims description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 claims description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
229920002101 Chitin Polymers 0.000 claims description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 2
229920000045 Dermatan sulfate Polymers 0.000 claims description 2
229920000855 Fucoidan Polymers 0.000 claims description 2
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
229920002527 Glycogen Polymers 0.000 claims description 2
229920002971 Heparan sulfate Polymers 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
229920000288 Keratan sulfate Polymers 0.000 claims description 2
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
229920001543 Laminarin Polymers 0.000 claims description 2
229920001491 Lentinan Polymers 0.000 claims description 2
229920001218 Pullulan Polymers 0.000 claims description 2
239000004373 Pullulan Substances 0.000 claims description 2
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims description 2
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 2
229940072056 alginate Drugs 0.000 claims description 2
235000010443 alginic acid Nutrition 0.000 claims description 2
229920000615 alginic acid Polymers 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 claims description 2
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
125000002029 aromatic hydrocarbon group Chemical group 0.000 claims description 2
239000000679 carrageenan Substances 0.000 claims description 2
235000010418 carrageenan Nutrition 0.000 claims description 2
229920001525 carrageenan Polymers 0.000 claims description 2
229940113118 carrageenan Drugs 0.000 claims description 2
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 2
229940051593 dermatan sulfate Drugs 0.000 claims description 2
229930182830 galactose Natural products 0.000 claims description 2
229960002442 glucosamine Drugs 0.000 claims description 2
229940097043 glucuronic acid Drugs 0.000 claims description 2
229940096919 glycogen Drugs 0.000 claims description 2
229920002674 hyaluronan Polymers 0.000 claims description 2
229960003160 hyaluronic acid Drugs 0.000 claims description 2
125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 2
DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 claims description 2
229940115286 lentinan Drugs 0.000 claims description 2
229920001277 pectin Polymers 0.000 claims description 2
239000001814 pectin Substances 0.000 claims description 2
235000010987 pectin Nutrition 0.000 claims description 2
235000019423 pullulan Nutrition 0.000 claims description 2
239000008107 starch Substances 0.000 claims description 2
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
229930091371 Fructose Natural products 0.000 claims 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
239000005715 Fructose Substances 0.000 claims 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
150000001735 carboxylic acids Chemical class 0.000 claims 1
238000006555 catalytic reaction Methods 0.000 claims 1
239000008103 glucose Substances 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
229940070765 laurate Drugs 0.000 claims 1
VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 19
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract description 11
241001430294 unidentified retrovirus Species 0.000 abstract description 7
POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 abstract description 6
IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract description 3
239000005639 Lauric acid Substances 0.000 abstract description 2
235000021314 Palmitic acid Nutrition 0.000 abstract description 2
239000003443 antiviral agent Substances 0.000 abstract 1
150000004945 aromatic hydrocarbons Chemical class 0.000 abstract 1
150000002430 hydrocarbons Chemical class 0.000 abstract 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 abstract 1
230000019635 sulfation Effects 0.000 description 36
238000005670 sulfation reaction Methods 0.000 description 36
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
230000010933 acylation Effects 0.000 description 29
238000005917 acylation reaction Methods 0.000 description 29
RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 25
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 21
238000004458 analytical method Methods 0.000 description 19
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 17
229910052717 sulfur Inorganic materials 0.000 description 17
238000012360 testing method Methods 0.000 description 17
239000000843 powder Substances 0.000 description 16
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
208000015181 infectious disease Diseases 0.000 description 14
210000004027 cell Anatomy 0.000 description 13
239000007795 chemical reaction product Substances 0.000 description 13
239000000203 mixture Substances 0.000 description 13
239000002609 medium Substances 0.000 description 9
210000004072 lung Anatomy 0.000 description 7
239000011734 sodium Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
230000029936 alkylation Effects 0.000 description 6
238000005804 alkylation reaction Methods 0.000 description 6
UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
230000023555 blood coagulation Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000000120 cytopathologic effect Effects 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
239000003651 drinking water Substances 0.000 description 4
235000020188 drinking water Nutrition 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
238000012545 processing Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000000108 ultra-filtration Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000003756 stirring Methods 0.000 description 3
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 3
229960005314 suramin Drugs 0.000 description 3
239000000725 suspension Substances 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
241000713325 Visna/maedi virus Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001347 alkyl bromides Chemical class 0.000 description 2
150000001351 alkyl iodides Chemical class 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
235000011180 diphosphates Nutrition 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
DUPBILVWMPJNKH-UHFFFAOYSA-N pyridine;sulfur dioxide Chemical compound O=S=O.C1=CC=NC=C1 DUPBILVWMPJNKH-UHFFFAOYSA-N 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010048685 Oral infection Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010047620 Phytohemagglutinins Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
230000010339 dilation Effects 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid group Chemical group C(CCCCCC)(=O)O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940043138 pentosan polysulfate Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
238000005375 photometry Methods 0.000 description 1
230000001885 phytohemagglutinin Effects 0.000 description 1
235000021110 pickles Nutrition 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000013587 production medium Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000017960 syncytium formation Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
210000003501 vero cell Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Polymers & Plastics (AREA)
Materials Engineering (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2170400A 1989-07-01 1990-06-29 置換されたポリサツカライドおよびその製法 Pending JPH0343401A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3921761A DE3921761A1 (de)	1989-07-01	1989-07-01	Substituierte polysaccharide, verfahren zu deren herstellung sowie deren verwendung zur prophylaxe und behandlung von viruserkrankungen
DE3921761.2		1989-07-01

Publications (1)

Publication Number	Publication Date
JPH0343401A true JPH0343401A (ja)	1991-02-25

Family

ID=6384152

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2170400A Pending JPH0343401A (ja)	1989-07-01	1990-06-29	置換されたポリサツカライドおよびその製法

Country Status (5)

Country	Link
EP (1)	EP0406685A1 (2)
JP (1)	JPH0343401A (2)
DE (1)	DE3921761A1 (2)
IE (1)	IE902384A1 (2)
TW (1)	TW197373B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5459257A (en) *	1993-01-11	1995-10-17	Dainippon Ink And Chemicals, Inc.	Sulfated oligoglycoside acylate and antiviral agent containing the same as active ingredient

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4021066A1 (de) *	1990-07-03	1992-01-09	Hoechst Ag	Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
WO1992013541A1 (de) *	1991-01-30	1992-08-20	Hoechst Aktiengesellschaft	Die verwendung substituierter polysaccharide zur behandlung von degenerativen gelenkerkrankungen
JPH05279381A (ja) *	1991-09-13	1993-10-26	Dainippon Ink & Chem Inc	硫酸化オリゴ糖芳香族配糖体
WO2000024784A1 (fr) *	1998-10-26	2000-05-04	Elena Alexandrovna Izaxon	Substance bioactive a base de dextran
WO2000034339A1 (fr) *	1998-12-04	2000-06-15	Iliya Yakovlevich Ashkinazi	N-arylamides de carboxymethyldextrane bioactifs
DK1733730T3 (da) *	2003-10-24	2008-10-13	Nutricia Nv	Immunmodulerende oligosaccharider
US7670678B2 (en)	2006-12-20	2010-03-02	The Procter & Gamble Company	Fibers comprising hemicellulose and processes for making same
US20080234476A1 (en)	2006-12-20	2008-09-25	The Procter & Gamble Company	Polysaccharide derivatives and structures employing same
AU2008100725B4 (en) *	2008-07-04	2008-10-02	Parnell Technologies Pty Ltd	A sulfated polysaccharide compound for clinical use
CN105037586A (zh) *	2015-06-08	2015-11-11	同济大学	一种抗凝血医用材料及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3478016A (en) *	1967-07-26	1969-11-11	Eastman Kodak Co	Preparation of cellulose ester and ether sulfates with low inorganic salt content
SU334840A1 (ru) *	1970-04-08	1976-07-25		Способ получени смещанных сульфатосодержащих эфиров целлюлозы
JPS5027884A (2) *	1973-07-12	1975-03-22
US4177345A (en) *	1974-07-10	1979-12-04	Schweiger Richard Georg	Process for preparing a sulfate ester of a polyhydroxy polymer
EP0240098A3 (en) *	1986-04-04	1989-05-10	Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo	Oligo and polysaccharides for the treatment of diseases caused by retroviruses
DE3821271A1 (de) *	1988-06-23	1989-12-28	Solco Basel Ag	Derivatisiertes heparin, verfahren zu dessen herstellung und arzneimittel, welches dieses enthaelt

1989
- 1989-07-01 DE DE3921761A patent/DE3921761A1/de not_active Withdrawn
1990
- 1990-06-27 EP EP90112230A patent/EP0406685A1/de not_active Withdrawn
- 1990-06-29 IE IE238490A patent/IE902384A1/en unknown
- 1990-06-29 JP JP2170400A patent/JPH0343401A/ja active Pending
- 1990-07-17 TW TW079105879A patent/TW197373B/zh active

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5459257A (en) *	1993-01-11	1995-10-17	Dainippon Ink And Chemicals, Inc.	Sulfated oligoglycoside acylate and antiviral agent containing the same as active ingredient

Also Published As

Publication number	Publication date
IE902384A1 (en)	1991-06-19
TW197373B (2)	1993-01-01
DE3921761A1 (de)	1991-01-03
EP0406685A1 (de)	1991-01-09

Publication	Publication Date	Title
Sosa et al.	1991	N-Carboxymethylchitosan-N, O-sulfate as an anti-HIV-1 agent
AU650626B2 (en)	1994-06-30	Method for producing soluble glucans
US5663324A (en)	1997-09-02	Method for producing underivatized, aqueous soluble β(1-3) glucan
DK168297B1 (da)	1994-03-07	Fremgangsmåde til fremstilling af lavmolekylær heparin ud fra normal heparin
AU642023B2 (en)	1993-10-07	Anti-virus agent
Baba et al.	1990	Novel sulfated polysaccharides: dissociation of anti-human immunodeficiency virus activity from antithrombin activity
JPH0343401A (ja)	1991-02-25	置換されたポリサツカライドおよびその製法
RU2552337C2 (ru)	2015-06-10	Сульфатированные гиалуроновые кислоты в качестве регуляторов цитокиновой активности
CA2046037A1 (en)	1992-01-04	Long-term prophylaxis against diseases caused by viruses or by unconventional viruses
CN105504097B (zh)	2018-07-03	一种硫酸化肝素寡糖及其制备方法和应用
IL154848A (en)	2010-11-30	Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative
JPH01279828A (ja)	1989-11-10	脈管形成阻止剤
US20110280829A1 (en)	2011-11-17	Low Molecular Weight Sulphated Polysaccharides as Candidates for Anti-Angiogenic Therapy
JP2012503683A (ja)	2012-02-09	オニノヤガラ多糖硫酸化誘導体、その製造方法及びその用途
CA1330305C (en)	1994-06-21	Heparin fragments and fractions with anti-hiv action
US5055457A (en)	1991-10-08	Pharmaceutical combinations product and the preparation and use thereof
JPH08277224A (ja)	1996-10-22	抗炎症剤
WO1990009181A1 (en)	1990-08-23	Anti-hiv drug
EP0338092A1 (en)	1989-10-25	Anti-hiv agent
WO2021215987A1 (en)	2021-10-28	Compositions and methods for use in the treatment of respiratory infections
KR910700269A (ko)	1991-03-14	신규 황산화 폴리사카라이드, 약학적으로 허용 가능한 그의 염, 이의 제조방법 및 유효성분으로서 이를 함유하는 약제
CN112870217B (zh)	2022-06-21	甘露葡萄糖醛酸多(寡)糖及其硫酸化衍生物在制备治疗骨质疏松症药物中的应用
JP6980018B2 (ja)	2021-12-15	内因系テンナーゼ複合体を阻害するオリゴ糖、その製造方法と用途
IE904033A1 (en)	1991-05-22	Polyelectrolyte complexes for the treatment and prophylaxis¹of virus diseases, novel polyelectrolyte complexes and a¹process for their preparation
US20030171333A1 (en)	2003-09-11	Pharmaceutical composition containing at least a polymer combined with or conjugated to at least a phenylalkylcarboxylic acid salt, conjugate polymers and uses thereof

JPH0343401A - 置換されたポリサツカライドおよびその製法 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=6384152

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (10)

Family Cites Families (6)

Cited By (1)

Also Published As

Similar Documents